-
2025-522051-26-00
5
2026-04-23
Acquired Angioedema due to C1 Inhibitor Deficiency
-
2025-522782-30-00
3
2026-04-07
CCI
-
2025-521142-22-00
5
2026-03-27
Hereditary Angioedema
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-522892-27-00
4
2026-03-21
Bronchiectasis
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2025-522437-65-00
4
2026-03-06
small-cell lung cancer
-
2024-516476-15-00
9
2026-03-04
Advanced gastrointestinal stromal tumor (GIST)
-
2025-523202-32-00
5
2026-02-26
Major Depressive Disorder
-
2024-519068-42-00
10
2026-02-12
Heterozygous Familial Hypercholesterolemia in pediatric patients
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521299-76-00
7
2025-12-18
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
-
2025-521276-59-00
5
2025-12-16
Autosomal dominant polycystic kidney disease (ADPKD)
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520794-39-00
5
2025-12-10
Arterial Hypertension
-
2025-521293-34-00
4
2025-12-09
Moderate-to-severe hidradenitis suppurativa
-
2024-519479-24-00
4
2025-11-21
metastatic colorectal cancer
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2025-521260-35-00
6
2025-11-07
acute ischemic stroke and atrial fibrillation (AF)